CS
BEAM icon

Candriam SCA’s Beam Therapeutics BEAM Stock Holding History

Candriam SCA’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-212,665
Closed -$5.79M – 700
2023
Q4 		$5.79M Buy
212,665
+83,000
+64% +$2.06M 0.04% 324
2023
Q3 		$3.12M Hold
129,665
– – 0.02% 374
2023
Q2 		$4.14M Buy
129,665
+50,000
+63% +$1.62M 0.03% 367
2023
Q1 		$2.25M Hold
79,665
– – 0.02% 554
2022
Q4 		$3.12M Hold
79,665
– – 0.02% 492
2022
Q3 		$3.79M Hold
79,665
– – 0.03% 444
2022
Q2 		$3.08M Buy
79,665
+2,518
+3% +$100K 0.03% 406
2022
Q1 		$4.42M Hold
77,147
– – 0.03% 374
2021
Q4 		$6.15M Hold
77,147
– – 0.04% 319
2021
Q3 		$6.71M Hold
77,147
– – 0.05% 335
2021
Q2 		$9.93M Buy
+77,147
New +$6.15M 0.07% 286

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Candriam SCA's BEAM Position: Q1 2024 in Review

Candriam SCA sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 212,665 shares — an estimated $5.79M sold.

Candriam SCA first reported a position in BEAM in Q2 2021 and held it in 11 quarters. The position peaked at $9.93M in Q2 2021. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Candriam SCA reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 212,665 Beam Therapeutics shares in Q1 2024, an estimated $5.79M.
  • Candriam SCA first reported a position in Beam Therapeutics in Q2 2021 and held it in 11 quarters.
  • Candriam SCA's Beam Therapeutics position peaked at $9.93M in Q2 2021.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.